Professor of Medicine
Internal Medicine
Dr. Alan P. Venook, MD
|
|
Give Review
Doctor Alan P. Venook, MD practices Internal Medicine. He went to University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical college. University of California San Francisco School of Medicine is ranked 3 in research and 3 in primary care medicine He over the years received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Alan Venook is a published doctor and has 93 publications published. The lastest was: 'Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.' Alan Venook is registered with Medicare.
Publications
- Gene Expression Profiling of Evening Fatigue in Women Undergoing Chemotherapy for Breast Cancer.
- Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?
- NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
- Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance).
- Clinical Cancer advances 2015: annual report on progress against Cancer from the american society of clinical oncology.
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
- Bone metastases and skeletal-related events from neuroendocrine Tumors.
- Aspirin and COX-2 inhibitor use in patients with stage III colon Cancer.
- Generalizability of trial results to elderly Medicare patients with advanced solid Tumors (Alliance 70802).
- A Case Series of Patients with HER2-Overexpressed Primary Metastatic GastroEsophageal Adenocarcinoma.
- Potent antitumor activity of Cabozantinib, a c-MET and VEGFR2 Inhibitor, in a Colorectal Cancer Patient-derived Tumor Explant Model.
- CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer.
- International Adaptations of NCCN Clinical Practice Guidelines in Oncology.
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes.
- Curable Patient With Metastatic Colorectal Cancer: Balancing Effective Therapies and Toxicities.
- (90)Y Glass Microspheres for the Treatment of Unresectable Metastatic Liver Disease from Chemotherapy-Refractory Gastrointestinal Cancers: A Pilot Study.
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance).
- A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal Cancer.
- Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance.
- Biomarkers in colon Cancer: the chasm between expectations and reality.
- The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
- Localized Colon Cancer, Version 3.2013.
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581.
- Metastatic Colon Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines.
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design.
- Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405.
- Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.
- Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain.
- When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression.
- Lymph Node Sampling Rates and Predictors of Nodal Metastasis in Pancreatic Neuroendocrine Tumor Resections: The UCSF Experience With 149 Patients.
- Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and Liver transplantation? Time for a multicenter trial.
- Metastatic colorectal Cancer: a curable disease.
- Biomarker use in colorectal Cancer therapy.
- Colon Cancer.
- Lactic acidosis and colon Cancer: oncologic emergency?
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.
- Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (cancer and Leukemia group B 80303).
- Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?
- Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced ...
- Adjuvant treatment of colon Cancer: what is next?
- "And what other medications are you taking?".
- Perineural invasion in pT3N0 rectal Cancer: the incidence and its prognostic effect.
- Long-term outcome of early-stage rectal Cancer undergoing standard resection and local excision.
- Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal Cancer.
- Nonadherence to imatinib during an economic downturn.
- Identification of unknown primary tumors in patients with neuroendocrine Liver metastases.
- Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
- The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.
- Drug development in advanced colorectal Cancer: challenges and opportunities.
- NCCN clinical practice guidelines in oncology: hepatobiliary Cancers.
- A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.
- Design issues in dose-finding Phase I trials for combinations of two agents.
- Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellula...
- Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic Cancer: is an anti-VEGF strate...
- Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic Cancer receiving chemotherapy.
- NCCN Task Force Report: mTOR inhibition in solid Tumors.
- The impact of new data in the treatment of advanced hepatocellular carcinoma.
- Responding to the rising incidence of hepatocellular carcinoma with targeted therapy.
- Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic Cancer: results of a phase II study.
- A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal Cancer hepatic metastases: Cancer...
- Hepatocellular carcinoma: the role of the North American GI Steering Committee HepatoBiliary Task Force and the advent of effective drug therapy.
- Section III: Treatment of Advanced Gastrointestinal Cancers.
- Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology.
- Section I: essentials of ensuring excellence in Cancer care.
- Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.
- Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine Cancer?
- A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic Cancer.
- Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated adva...
- Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast Cancer metastatic to the liver.
- Chemotherapy and regional therapy of hepatic coloRectal metastases: expert consensus statement.
- Phase II study of recombinant human endostatin in patients with advanced neuroendocrine Tumors.
- The cancer and Leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
- Targeted therapy in colorectal Cancer.
- Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
- Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adeno...
- Epidermal growth factor receptor-targeted treatment for advanced coloRectal carcinoma.
- Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorect...
- Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
- Cetuximab in the treatment of colorectal Cancer.
- Emerging therapies for metastatic colorectal Cancer: focus on EGFR and VEGF inhibition.
- Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experien...
- Induction therapy in patients with metastatic colorectal Cancer.
- ColoRectal metastases confined to the liver: a unique opportunity?
- Testing the water before diving off the cutting edge.
- Shedding old paradigms: developing viruses to treat Cancer.
- Biologic Agents in the Treatment of Colorectal Cancer.
- Novel Therapeutics in Hepatocellular Carcinoma.
- Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance).
- Colorectal Cancer: all hands on deck.
Schools
University Of California San Francisco School Of Medicine
University Of California Davis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of California Davis -
University of California San Francisco School of Medicine
Hospital
-
UCSF Medical Center -
San Francisco VA Medical Center
Drug Facts
| NPI NUMBER | 1487618831 | |
| NPPES Provider LastName | VENOOK | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 941430001 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 25.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487618831 |
| Last Name Of The Provider | VENOOK |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
|
Dr. Meghana Gadgil, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Reynaldo M. Cordero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dace B. Mitchell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric Geiser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sweta M. Patel, MD |
|
|
Dr. Bertrand Y. Tuan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Niharika Dixit, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laurence M. Corash, MD |
|
|
Dr. Wen Jing, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Nystrom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claire M. Campbell, MD |